platform performs highly sensitive mutation detection to enable accurate tumor profiling and real-time monitoring of tumor evolution from cell-free DNA in plasma. The OnTarget assay is available as a research-use service to reveal tumor mutations that are undetectable with other methods and may help guide selection of therapy, improve clinical trial efficiency, and accelerate drug development programs.

Boreal Genomics was founded in 2007 and is based in Vancouver, BC, Canada.